IL-1β-dependent neurological effects of the whole cell pertussis vaccine: A role for IL-1-associated signalling components in vaccine reactogenicity

Journal of Neuroimmunology

Volumn 136, Issue 1-2, 2003, Pages 25-33

  Armstrong, Michelle E ^a   Loscher, Christine E ^a   Lynch, Marina A ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Hypothalamus; IL 1 receptors; IL 1ra; IL 1 ; Pertussis vaccines; Stress activated kinases

Indexed keywords

ACELLULAR VACCINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; PERTUSSIS VACCINE; STRESS ACTIVATED PROTEIN KINASE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SIALOGLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HYPOTHALAMUS; IMMUNIZATION; INFLAMMATION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; CASPASE 1; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HYPOTHALAMUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERTUSSIS VACCINE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-1 TYPE II; RNA, MESSENGER; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION;

EID: 0037333723     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00468-X     Document Type: Article

References (58)

1. Ausiello C.M., Fedele G., Urbani F., Lande R., Di Carlo B., Cassone A. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J. Infect. Dis. 186:2002;351-360.
2. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 2:1995;241-248.
3. Beckman M.J., Sotos J., Schuler L.A., Czuprynski C.J. Differential gene regulation of interleukin-1 ligands and receptors in bovine peripheral blood neutrophils and mononuclear cells in response to E. coli lipopolysaccharide (LPS). Vet. Immunol. Immunopathol. 77:2000;221-232.
4. Bhat R.V., DiRocco R., Marcy V.R., Flood D.G., Zhu Y., Dobrzanski P., Siman R., Scott R., Contreras P.C., Miller M. Increased expression of IL-1beta converting enzyme in hippocampus after ischaemia: selective localization in microglia. J. Neurosci. 16:1996;4146-5414.
5. Black R.A., Kronheim S.R., Cantrell M., Deeley M.C., March C.J., Prickett K.S., Wignall J., Conlon P.J., Cosman D., Hopp T.P., Mochizuki D.Y. Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J. Biol. Chem. 263:1988;9437-9442.
6. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principal of protein-dye binding. Anal. Biochem. 72:1976;248-254.
7. Cartmell T., Luheshi G.N., Hopkins S.J., Rothwell N.J., Poole S. Role of endogenous interleukin-receptor antagonist in regulating fever by localised inflammation in the rat. J. Physiol. 531.1:2001;171-180.
8. Cherry J.D., Brunnell P.A., Golden G.S., Karzon D.T. Report of the task force on pertussis immunization. Pediatrics. 81:1988;939-984.
9. Colotta F., Dower S.K., Sims J.E., Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin-1. Immunol. Today. 15:1994;562-566.
10. Dinarello C.A. Biology of interleukin-1. FASEB J. 2:1988;108-115.
11. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
12. Dinarello C.A. The role of interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343:2000;732-734.
13. Dinarello C.A., Gatti S., Bartfai T. Fever: links with an ancient receptor. Curr. Biol. 9:1999;R147-R150.
14. Donnelly S., Loscher C.E., Lynch M.A., Mills K.H.G. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination. Infect. Immun. 69:2001;4217-4223.
15. Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T., Hannum C.H., Thompson R.C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 343:1990;341-346.
16. Farrar W.L., Hill J.M., Harel-Bellan A., Vinocour M. The immune logical brain. Immunol. Rev. 100:1987;361-378.
17. Gabellec M.-M., Griffais R., Fillion G., Haour F. Expression of interleukin-1α, interleukin-1β and interleukin-1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain. Res. Mol. Brain. Res. 31:1995;122-130.
18. Gabellec M.-M., Griffais R., Fillion G., Haour F. Interleukin-1 receptors type I and type II in the mouse brain: kinetics of mRNA expression after peripheral administration of bacterial lipopolysaccharide. J. Neuroimmunol. 66:1996;65-70.
19. Gabellec M.-M., Jafarian-Tehrani M., Griffais R., Haour F. Interleukin-1 receptor accessory protein transcripts in the brain and spleen: kinetics after peripheral administration of bacterial lipopolysaccharide in mice. Neuroimmunomodulation. 3:1996;304-309.
20. Giulian D., Baker T.J., Shih L.C., Lachman L.B. Interleukin 1 of the central nervous system is produced by ameboid microglia. J. Exp. Med. 164:1986;594-604.
21. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofi degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D., Wassilak S.G. A controlled trial of two cellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334:1996;341-348.
22. Greenfeder S.A., Nunes P., Kwee L., Labow M., Chizzonite R.A., Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270:1995;13757-13765.
23. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
24. Gutierrez E.G., Banks W.A., Kastin A.J. Murine tumour necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 47:1993;169-176.
25. Gutierrez E.G., Banks W.A., Kastin A.J. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J. Neuroimmunol. 55:1994;153-160.
26. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., Armes L.G., Sommer A., Eisenberg S.P., Thompson R.C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 343:1990;336-340.
27. Lang D., Knop J., Wesche H., Raffetseder U., Kurrle R., Boraschi D., Martin M.U. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J. Immunol. 161:1998;6871-6877.
28. Lechan R.M., Toni R., Clark B.D., Cannon J.G., Shaw A.R., Dinarello C.A., Reichlin S. Immunoreactive interleukin-1 beta localization in the rat forebrain. Brain Res. 514:1990;135-140.
29. Loscher C.E., Donnelly S., McBennett S., Lynch M.A., Mills K.H.G. Proinflammatory cytokines in the adverse systemic and neurological effects associated with parenteral injection of a whole cell pertussis vaccine. Ann. N.Y. Acad. Sci. 856:1998;274-277.
30. Loscher C.E., Donnelly S., Lynch M.A., Mills K.H.G. Induction of inflammatory cytokines in the brain following respiratory infection with Bordetella pertussis. J. Neuroimmunol. 102:2000;172-181.
31. Loscher C.E., Donnelly S., Mills K.H.G., Lynch M.A. Interleukin-1beta-dependent changes in the hippocampus following parenteral immunization with a whole cell pertussis vaccine. J. Neuroimmunol. 111:2000;68-76.
32. Maness L.M., Kastin A.J., Banks W.A. Relative contributions of a CVO and the microvascular bed to delivery of blood-borne IL-1α to the brain. Endocrinol. Metab. 38:1998;E207-E212.
33. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight E., Murphy C.A., Bartlett B.A., Finn J.P., Angeles T., Matsuda Y., Neff N.T., Dionne C.A. Motorneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signalling pathway. J. Neurosci. 18:1998;104-111.
34. Martinou J.-C., Sadoul R. ICE-like proteases execute the neuronal death program. Curr. Opin. Neurobiol. 6:1996;609-614.
35. McGuirk P., Mills K.H.G. A regulatory role for IL-4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect. Immun. 68:2000;1383-1391.
36. McGuirk P., Mills K.H.G. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous haemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30:2000;415-422.
37. McGuirk P., McCann C., Mills K.H.G. Pathogen-specific T regulatory 1 (Tr1) cells induced in the respiratory tract by a bacterial molecule that stimulates IL-10 production by dendritic cells: a novel strategy for evasion of protective Th1 responses against Bordetella pertussis. J. Exp. Med. 195:2002;221-231.
38. McMahan C.J., Slack J.L., Mosley B., Cosman D., Lupton S.D., Brunton L.L., Grubin C.E., Wignall J.M., Jenkins N.A., Brannan C.I. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10:1991;2821-2832.
39. Miller D.L., Ross E.M., Alderslade R., Bellman M.H., Rawson N.S. Pertussis immunisation and serious acute neurological illness in children. Br. Med. J. 282:1981;1595-1599.
40. Mills K.H.G. Induction and detection of T cell responses. Robinson A. Methods in Molecular Medicine-Vaccine Protocols. 1996;197-221 Humana Press, New Jersey, USA.
41. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211:1996;13-16.
42. Nagano I., Takao T., Nanamiya W., Hashimoto K. Modulation of type I interleukin-1 receptor messenger RNA followed by one and repeated endotoxin treatment in the mouse. J. Neuroimmunol. 195:2000;154-160.
43. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component cellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 350:1997;1569-1577.
44. Oppenheim J.J., Kovacs E.J., Matushima K., Durum S.K. There is more than one interleukin 1. Immunol. Today. 7:1986;45-56.
45. Park D.S., Stefanis L., Yan C.Y.I., Farinelli S.E., Greene L.A. Ordering the cell death pathway. J. Biol. Chem. 271:1996;21898-21905.
46. Parker L.C., Rushford D.A., Rothwell N.J., Luheshi G.N. IL-1β induced changes in hypothalamic IL-1RI and IL-1RII expression in the rat. Mol. Brain Res. 79:2000;156-158.
47. Penton-Rol G., Orlando S., Polentarutti N., Bernasconi S., Muzio M., Introna M., Mantovani A. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition on mRNA expression of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction on incompletely spliced transcripts. J. Immunol. 162:1999;2931-2938.
48. Re F., Sironi M., Muzio M., Matteuci C., Introna M., Orlando S., Penton-Rol G., Dower S.K., Sims J.E., Colotta F., Mantovani A. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J. Exp. Med. 183:1996;1841-1850.
49. Roth J., de Souza G.E.P. Fever induction pathways: evidence from responses to systemic or local cytokine formation. Braz. J. Med. Biol. Res. 34:2001;301-314.
50. Sidey F.M., Furmean B.L., Wardlaw A.C. Effect of hyperactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice. Vaccine. 7:1989;237-241.
51. Sims J.E., March C.J., Cosman D., Widmer M.B., MacDonald H.R., McMahan C.J., Grubin C.E., Wignall J.M., Jackson J.L., Call S.M. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science. 241:1988;585-589.
52. Symons J.A., Eastgate J.A., Duff G.W. Purification and characterization of a novel soluble receptor for interleukin 1. J. Exp. Med. 174:1991;1251-1254.
53. Touzani O., Boutin H., Chuquet J., Rothwell N. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J. Neuroimmunol. 100:1999;203-215.
54. Vereker E., O'Donnell E., Lynch M.A. The inhibitory effect of interleukin-1beta on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 20:2000;6811-6819.
55. Watt J.A., Hobbs N.K. Interleukin-1beta immunoreactivity in identified neurons of the rat magnocellular neurosecretory system: evidence for activity-dependent release. J. Neurosci. Res. 60:2000;478-489.
56. Wesche H., Neumann D., Resch K., Martin M.U. Co-expression of mRNA for type I and type II interlukin-1 receptors and the IL-1 receptor accessory protein correlates to IL-1 responsiveness. FEBS Lett. 391:1996;104-108.
57. Wong M., Bongiorno P., Rettori V., McCann S., Licinio J. Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10 and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc. Natl. Acad. Sci. U. S. A. 94:1997;227-232.
58. Yao J., Keri J.E., Taffs R.E., Colton C.A. Characterization of interleukin-1 production by microglia in culture. Brain Res. 591:1992;88-93.